Aptamer modification improves the adenoviral transduction of malignant glioma cells

Journal of Biotechnology

Volumn 168, Issue 4, 2013, Pages 362-366

  Chen, Hao ^a   Zheng, Xiaojing ^a   Di, BingYan ^a   Wang, Dongyang ^a   Zhang, Yaling ^a   Xia, Haibin ^a   Mao, Qinwen ^b  

^a SHAANXI NORMAL UNIVERSITY   (China)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Adenovirus; Aptamer; Biotin acceptor peptide (BAP); Hexon; Targeted tumor therapy

Indexed keywords

ADENOVIRUS; APTAMERS; BIOTIN ACCEPTOR; HEXON; TUMOR THERAPY;

BACTERIOPHAGES; CELL CULTURE; COENZYMES; GENE THERAPY; OLIGONUCLEOTIDES; PEPTIDES; TUMORS;

CELLS;

ADENOVIRUS SEROTYPE 5; ADENOVIRUS VECTOR; APTAMER; AVIDIN; BIOTIN; NUCLEOLIN; TENASCIN; UNCLASSIFIED DRUG;

ARTICLE; BIOTINYLATION; CELL STRAIN HEK293; CELL SURFACE; CHEMICAL MODIFICATION; CONTROLLED STUDY; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE;

ADENOVIRIDAE; APTAMERS, NUCLEOTIDE; AVIDIN; BIOTIN; COXSACKIE AND ADENOVIRUS RECEPTOR-LIKE MEMBRANE PROTEIN; GENETIC THERAPY; GENETIC VECTORS; GLIOMA; HEK293 CELLS; HUMANS; TRANSDUCTION, GENETIC;

EID: 84888819799     PISSN: 01681656     EISSN: 18734863     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2013.10.024     Document Type: Article

References (47)

1. Anderson R.D., Haskell R.E., Xia H., Roessler B.J., Davidson B.L. A simple method for the rapid generation of recombinant adenovirus vectors. Gene Ther. 2000, 7:1034-1038.
2. Barbas A.S., Mi J., Clary B.M., White R.R. Aptamer applications for targeted cancer therapy. Future Oncol. 2010, 6:1117-1126.
3. Barnett B.G., Crews C.J., Douglas J.T. Targeted adenoviral vectors. Biochim. Biophys. Acta 2002, 1575:1-14.
4. Bergelson J.M., Cunningham J.A., Droguett G., Kurt-Jones E.A., Krithivas A., Hong J.S., Horwitz M.S., Crowell R.L., Finberg R.W. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997, 275:1320-1323.
5. Boltz A., Piater B., Toleikis L., Guenther R., Kolmar H., Hock B. Bi-specific aptamers mediating tumor cell lysis. J. Biol. Chem. 2011, 286:21896-21905.
6. Campos S.K., Parrott M.B., Barry M.A. Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector. Mol. Ther. 2004, 9:942-954.
7. Cerchia L., De Franciscis V. Nucleic acid-based aptamers as promising therapeutics in neoplastic diseases. Methods Mol. Biol. 2007, 361:187-200.
8. Cerchia L., Esposito C.L., Jacobs A.H., Tavitian B., De Franciscis V. Differential SELEX in human glioma cell lines. PLoS One 2009, 4:e7971.
9. Cerchia L., Hamm J., Libri D., Tavitian B., De Franciscis V. Nucleic acid aptamers in cancer medicine. FEBS Lett. 2002, 528:12-16.
10. Crompton J., Toogood C.I., Wallis N., Hay R.T. Expression of a foreign epitope on the surface of the adenovirus hexon. J. Gen. Virol. 1994, 75(Pt 1):133-139.
11. Daniels D.A., Chen H., Hicke B.J., Swiderek K.M., Gold L. A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc. Natl. Acad. Sci. U S A 2003, 100:15416-15421.
12. Di B., Mao Q., Zhao J., Li X., Wang D., Xia H. A rapid generation of adenovirus vector with a genetic modification in hexon protein. J. Biotechnol. 2012, 157:373-378.
13. Di Giusto D.A., Knox S.M., Lai Y., Tyrelle G.D., Aung M.T., King G.C. Multitasking by multivalent circular DNA aptamers. Chembiochem 2006, 7:535-544.
14. Dmitriev I., Krasnykh V., Miller C.R., Wang M., Kashentseva E., Mikheeva G., Belousova N., Curiel D.T. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol. 1998, 72:9706-9713.
15. Einfeld D.A., Brough D.E., Roelvink P.W., Kovesdi I., Wickham T.J. Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base. J. Virol. 1999, 73:9130-91366.
16. Gao J.Q., Eto Y., Yoshioka Y., Sekiguchi F., Kurachi S., Morishige T., Yao X., Watanabe H., Asavatanabodee R., Sakurai F., Mizuguchi H., Okada Y., Mukai Y., Tsutsumi Y., Mayumi T., Okada N., Nakagawa S. Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration. J. Control. Release 2007, 122:102-110.
17. Glasgow J.N., Everts M., Curiel D.T. Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther. 2006, 13:830-844.
18. Guo J., Gao X., Su L., Xia H., Gu G., Pang Z., Jiang X., Yao L., Chen J., Chen H. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials 2011, 32:8010-8020.
19. Hovanessian A.G., Soundaramourty C., El Khoury D., Nondier I., Svab J., Krust B. Surface expressed nucleolin is constantly induced in tumor cells to mediate calcium-dependent ligand internalization. PLoS One 2010, 5:e15787.
20. Israel B.F., Pickles R.J., Segal D.M., Gerard R.D., Kenney S.C. Enhancement of adenovirus vector entry into CD70-positive B-cell Lines by using a bispecific CD70-adenovirus fiber antibody. J. Virol. 2001, 75:5215-5221.
21. Jullienne B., Vigant F., Muth E., Chaligne R., Bouquet C., Giraudier S., Perricaudet M., Benihoud K. Efficient delivery of angiostatin K1-5 into tumors following insertion of an NGR peptide into adenovirus capsid. Gene Ther. 2009, 16:1405-1415.
22. Kashentseva E.A., Seki T., Curiel D.T., Dmitriev I.P. Adenovirus targeting to c-erbB-2 oncoprotein by single-chain antibody fused to trimeric form of adenovirus receptor ectodomain. Cancer Res. 2002, 62:609-616.
23. Kim M., Sumerel L.A., Belousova N., Lyons G.R., Carey D.E., Krasnykh V., Douglas J.T. The coxsackievirus and adenovirus receptor acts as a tumour suppressor in malignant glioma cells. Br. J. Cancer. 2003, 88:1411-1416.
24. Kurachi S., Koizumi N., Sakurai F., Kawabata K., Sakurai H., Nakagawa S., Hayakawa T., Mizuguchi H. Characterization of capsid-modified adenovirus vectors containing heterologous peptides in the fiber knob. Protein IX, or Hexon. Gene Ther. 2007, 14:266-274.
25. Lamfers M.L., Grill J., Dirven C.M., Van Beusechem V.W., Geoerger B., Van Den Berg J., Alemany R., Fueyo J., Curiel D.T., Vassal G., Pinedo H.M., Vandertop W.P., Gerritsen W.R. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res. 2002, 62:5736-5742.
26. Lenaerts L., Van Dam W., Persoons L., Naesens L. Interaction between mouse adenovirus type 1 and cell surface heparan sulfate proteoglycans. PLoS One 2012, 7:e31454.
27. Li H.J., Everts M., Pereboeva L., Komarova S., Idan A., Curiel D.T., Herschman H.R. Adenovirus tumor targeting and hepatic untargeting by a coxsackie/adenovirus receptor ectodomain anti-carcinoembryonic antigen bispecific adapter. Cancer Res. 2007, 67:5354-5361.
28. Liu S., Mao Q., Zhang W., Zheng X., Bian Y., Wang D., Li H., Chai L., Zhao J., Xia H. Genetically modified adenoviral vector with the protein transduction domain of Tat improves gene transfer to CAR-deficient cells. Biosci. Rep. 2009, 29:103-109.
29. Mcnamara J.O., Kolonias D., Pastor F., Mittler R.S., Chen L., Giangrande P.H., Sullenger B., Gilboa E. Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J. Clin. Invest. 2008, 118:376-386.
30. Murphy A.M., Rabkin S.D. Current status of gene therapy for brain tumors. Transl. Res. 2013, 161:339-354.
31. Nabel G.J. Development of optimized vectors for gene therapy. Proc. Natl. Acad. Sci. U S A 1999, 96:324-326.
32. Nandi S., Lesniak M.S. Adenoviral virotherapy for malignant brain tumors. Expert Opin. Biol. Ther. 2009, 9:737-747.
33. Neff C.P., Zhou J., Remling L., Kuruvilla J., Zhang J., Li H., Smith D.D., Swiderski P., Rossi J.J., Akkina R. An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci. Transl. Med. 2011, 3:66ra6.
34. Ni X., Castanares M., Mukherjee A., Lupold S.E. Nucleic acid aptamers: clinical applications and promising new horizons. Curr. Med. Chem. 2011, 18:4206-4214.
35. Pedersini R., Vattemi E., Claudio P.P. Adenoviral gene therapy in high-grade malignant glioma. Drug News Perspect. 2010, 23:368-379.
36. Reche P.A. Lipoylating and biotinylating enzymes contain a homologous catalytic module. Protein Sci. 2000, 9:1922-1929.
37. Stoltenburg R., Reinemann C., Strehlitz B. SELEX--a (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol. Eng. 2007, 24:381-403.
38. Suzuki-Kouyama E., Katayama K., Sakurai F., Yamaguchi T., Kurachi S., Kawabata K., Nakagawa S., Mizuguchi H. Hexon-specific PEGylated adenovirus vectors utilizing avidin-biotin interaction. Biomaterials 2011, 32:1724-1730.
39. Thomas R.P., Recht L., Nagpal S. Advances in the management of glioblastoma: the role of temozolomide and MGMT testing. Clin. Pharmacol. 2013, 5:1-9.
40. Tomko R.P., Xu R., Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl. Acad. Sci. U S A 1997, 94:3352-3356.
41. Tuerk C., Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249:505-510.
42. Vigne E., Mahfouz I., Dedieu J.F., Brie A., Perricaudet M., Yeh P. RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J. Virol. 1999, 73:5156-5161.
43. Wang D., Liu S., Mao Q., Zhao J., Xia H. A novel vector for a rapid generation of fiber-mutant adenovirus based on one step ligation and quick screening of positive clones. J. Biotechnol. 2011, 152:72-76.
44. Wilson D.S., Szostak J.W. In vitro selection of functional nucleic acids. Annu. Rev. Biochem. 1999, 68:611-647.
45. Wortmann A., Vohringer S., Engler T., Corjon S., Schirmbeck R., Reimann J., Kochanek S., Kreppel F. Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol. Ther. 2008, 16:154-162.
46. Wu H., Han T., Belousova N., Krasnykh V., Kashentseva E., Dmitriev I., Kataram M., Mahasreshti P.J., Curiel D.T. Identification of sites in adenovirus hexon for foreign peptide incorporation. J. Virol. 2005, 79:3382-3390.
47. Yao X., Yoshioka Y., Morishige T., Eto Y., Watanabe H., Okada Y., Mizuguchi H., Mukai Y., Okada N., Nakagawa S. Systemic administration of a PEGylated adenovirus vector with a cancer-specific promoter is effective in a mouse model of metastasis. Gene Ther. 2009, 16:1395-1404.